Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on ESPR. StockNews.com downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.83.
Check Out Our Latest Report on ESPR
Esperion Therapeutics Stock Performance
Institutional Investors Weigh In On Esperion Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BOKF NA bought a new stake in Esperion Therapeutics in the 2nd quarter worth approximately $26,000. Herbst Group LLC purchased a new position in shares of Esperion Therapeutics in the 1st quarter worth $28,000. Private Portfolio Partners LLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $30,000. CVI Holdings LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $37,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Esperion Therapeutics during the first quarter worth $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
- Five stocks we like better than Esperion Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- How to Invest in Silver: A Beginner’s Guide
- Pros And Cons Of Monthly Dividend Stocks
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Why Are These Companies Considered Blue Chips?
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.